Format

Send to

Choose Destination
Neurology. 2017 Apr 4;88(14):1340-1348. doi: 10.1212/WNL.0000000000003796. Epub 2017 Mar 3.

DPPX antibody-associated encephalitis: Main syndrome and antibody effects.

Author information

1
From the Clinical and Experimental Neuroimmunology Program (M.H., H.A., M.P.-P., L.S., E.M.-H., M.R.R., F.G., J.D.), August Pi Sunyer Biomedical Research Institute, Hospital Clínic, University of Barcelona, Spain; Division of Neurology (M.H.), Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Biomedical Research Networking Centre for Rare Diseases (H.A., J.D., M.P.-P., L.S., E.M.-H., M.R.R.), Valencia, Spain; Departments of Neurology (M.J.T.) and Immunology (M.W.J.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Department of Neurology (M.R.R., J.D.), University of Pennsylvania, Philadelphia; and Catalan Institution for Research and Advanced Studies (J.D.), Barcelona, Spain.
2
From the Clinical and Experimental Neuroimmunology Program (M.H., H.A., M.P.-P., L.S., E.M.-H., M.R.R., F.G., J.D.), August Pi Sunyer Biomedical Research Institute, Hospital Clínic, University of Barcelona, Spain; Division of Neurology (M.H.), Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Biomedical Research Networking Centre for Rare Diseases (H.A., J.D., M.P.-P., L.S., E.M.-H., M.R.R.), Valencia, Spain; Departments of Neurology (M.J.T.) and Immunology (M.W.J.S.), Erasmus Medical Center, Rotterdam, the Netherlands; Department of Neurology (M.R.R., J.D.), University of Pennsylvania, Philadelphia; and Catalan Institution for Research and Advanced Studies (J.D.), Barcelona, Spain. Jdalmau@clinic.cat.

Abstract

OBJECTIVE:

To report the main syndrome of dipeptidyl-peptidase-like protein 6 (DPPX) antibody-associated encephalitis, immunoglobulin G (IgG) subclass, and the antibody effects on DPPX/Kv4.2 potassium channels.

METHODS:

A retrospective analysis of new patients and cases reported since 2013 was performed. IgG subclass and effects of antibodies on cultured neurons were determined with described techniques.

RESULTS:

Nine new patients were identified (median age 57 years, range 36-69 years). All developed severe prodromal weight loss or diarrhea followed by cognitive dysfunction (9), memory deficits (5), CNS hyperexcitability (8; hyperekplexia, myoclonus, tremor, or seizures), or brainstem or cerebellar dysfunction (7). The peak of the disease was reached 8 months (range 1-54 months) after onset. All patients had both IgG4 and IgG1 DPPX antibodies. In cultured neurons, the antibodies caused a decrease of DPPX clusters and Kv4.2 protein that was reversible on removal of the antibodies. Considering the current series and previously reported cases (total 39), 67% developed the triad: weight loss (median 20 kg; range 8-53 kg)/gastrointestinal symptoms, cognitive-mental dysfunction, and CNS hyperexcitability. Outcome was available from 35 patients (8 not treated with immunotherapy): 60% had substantial or moderate improvement, 23% had no improvement (most of them not treated), and 17% died. Relapses occurred in 8 of 35 patients (23%) and were responsive to immunotherapy.

CONCLUSIONS:

DPPX antibodies are predominantly IgG1 and IgG4 and associate with cognitive-mental deficits and symptoms of CNS hyperexcitability that are usually preceded by diarrhea, other gastrointestinal symptoms, and weight loss. The disorder is responsive to immunotherapy, and this is supported by the reversibility of the antibody effects in cultured neurons.

PMID:
28258082
PMCID:
PMC5379928
DOI:
10.1212/WNL.0000000000003796
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center